Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mind Medicine (MindMed) Inc
Total Equity
Mind Medicine (MindMed) Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Total Equity
$130.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
46%
|
CAGR 10-Years
84%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Total Equity
-$554m
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Total Equity
CA$758.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
19%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Total Equity
CA$1.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Total Equity
$1.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
63%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Total Equity
CA$766.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Mind Medicine (MindMed) Inc
Glance View
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
See Also
What is Mind Medicine (MindMed) Inc's Total Equity?
Total Equity
130.6m
USD
Based on the financial report for Sep 30, 2025, Mind Medicine (MindMed) Inc's Total Equity amounts to 130.6m USD.
What is Mind Medicine (MindMed) Inc's Total Equity growth rate?
Total Equity CAGR 10Y
84%
Over the last year, the Total Equity growth was -50%. The average annual Total Equity growth rates for Mind Medicine (MindMed) Inc have been -5% over the past three years , 46% over the past five years , and 84% over the past ten years .
